VTYX Q3 2021 Earnings — Ventyx Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

VTYXVentyx Biosciences, Inc.

$1B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$13M

Net Income

-$13M

EPS (Diluted)

$-0.27

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$969,000

Balance Sheet

Total Assets

$149M

Total Liabilities

$236M

Stockholders' Equity

-$88M

Cash & Equivalents

$69M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$13M	-$2M	-472.1%
Net Income	-$13M	-$7M	-78.5%